Breast cancer
Conditions
Interventions
Sponsors
The fist hospital of china medical university
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. Histopathological examination confirmed invasive breast cancer with positive HER2; 3. The tumor stage is early or locally advanced; 4. To receive a regimen containing pyrotinib as neoadjuvant therapy; 5. If targeted drugs are changed during neoadjuvant therapy, it is required that the last targeted drugs used preoperatively include pyrotinib; 6. Surgery has been performed and pathological examination results are available; 7. Have traceable medical history.
Exclusion criteria
Exclusion criteria: 1. Prior anti-tumor therapy or radiation therapy for any malignancy, not including cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma; 2. Patients who received other TKI anti-HER2 therapies during neoadjuvant therapy; 3. Patients enrolled in other studies; 4. The Investigator considers the patient unsuitable for participation in any other condition of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| total pathological complete remission;objective remission rate;safety; | — |
Countries
China
Contacts
Public ContactJin Feng
The fist hospital of china medical university
Outcome results
None listed